Gastric Cancer Clinical Trial
Official title:
Quality of Life Among Long-Term Survivors of Resected Gastric Cancer
The purpose of this study is to find out how you feel about the quality of your life after having had surgery to remove your stomach tumor. Some patients continue to experience different problems after stomach surgery, even when the surgery was more than three years ago. The purpose of this study is to find out the specific things that may continue to affect patients' quality of life after a major operation.
The purpose of this study is to measure the quality of life (QOL) of long-term survivors of
resected gastric cancer. This cohort of long-term survivors will include patients who have
no evidence of disease (NED) at least three years after having curative resection for
gastric cancer. There are three main types of surgical procedures used to resect primary
gastric cancer, which include proximal subtotal, distal subtotal, and total gastrectomy.
Surgical management of gastric cancer at Memorial Sloan-Kettering Cancer Center (MSKCC) has
shifted over the years to a greater use of proximal subtotal gastrectomies than in the past;
however the effects on the QOL of these patients are unknown. In this study, we propose to
use the European Organization for Research Treatment of Cancer (EORTC) two-part
questionnaire QLQ-C30 and QLQ-STO22. This instrument has been shown to be a valid and
reliable QOL instrument used to assess the quality of life of patients with gastric cancer.
We will measure multiple domains of QOL including, physical, role, cognitive, and emotional
functions. An additional 10-item questionnaire (MSK-10) was designed by GMT service surgeons
and will be administered in order to more specifically identify certain potential issues of
QOL among gastric cancer survivors. These issues include eating capabilities, work status
and major life changing events. Patients will be identified using the Gastric and Mixed
Tumor (GMT) Service Gastric Cancer Database. The questionnaires will be conducted via
telephone interview. Establishing these QOL measurements will help to provide valuable
baseline data upon which to base future clinical trials of optimal surgical techniques.
OBJECTIVES AND SCIENTIFIC AIMS
- To establish health related QOL using the EORTC QLQ-C30 and QLQ-STO22 in gastric cancer
patients who are alive and free of disease for three or more years after a proximal,
distal, or total gastrectomy for gastric cancer.
- To compare the differences in QOL scores between the three different types of
gastrectomy.
- To compare results using the EORTC QLQ-C30 with published norms established in the
United States.
- To use the MSK-10 to assess the incidence and degree of certain areas of QOL that may
affect gastric cancer survivors specifically.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05551416 -
The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
|
||
| Completed |
NCT05518929 -
Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
|
Phase 4 | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03219593 -
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Recruiting |
NCT05536102 -
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
| Active, not recruiting |
NCT04082364 -
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT03766607 -
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
|
Phase 2 | |
| Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
| Completed |
NCT01924533 -
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
|
Phase 3 | |
| Terminated |
NCT01641939 -
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT04908813 -
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04249739 -
Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
|
Phase 2 | |
| Recruiting |
NCT05514158 -
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)
|
Phase 1 | |
| Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 |